Press Releases Year None2020201920182017201620152014 March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic March 26, 2020 Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma March 10, 2020 Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results March 5, 2020 Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma February 25, 2020 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 February 12, 2020 Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference January 20, 2020 Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
Press Releases Year None2020201920182017201620152014 March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic March 26, 2020 Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma March 10, 2020 Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results March 5, 2020 Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma February 25, 2020 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 February 12, 2020 Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference January 20, 2020 Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic
March 26, 2020 Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma
March 5, 2020 Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma
February 25, 2020 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020
February 12, 2020 Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
January 20, 2020 Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma
January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
